Erratum: Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients with Crohn Disease: Posthoc Analysis of the LOVE-CD Study (Inflammatory Bowel Diseases DOI: 10.1093/ibd/izab143)

Jurij Hanzel; Erwin Dreesen; Séverine Vermeire; Mark Löwenberg; Frank Hoentjen; Peter Bossuyt; Esmé Clasquin; Filip J. Baert; Geert R. D'Haens; Ron Mathôt

doi:10.1093/ibd/izab270

Erratum: Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients with Crohn Disease: Posthoc Analysis of the LOVE-CD Study (Inflammatory Bowel Diseases DOI: 10.1093/ibd/izab143)

Jurij Hanzel
, Erwin Dreesen
, Séverine Vermeire
, Mark Löwenberg
, Frank Hoentjen
, Peter Bossuyt
, Esmé Clasquin
, Filip J. Baert
, Geert R. D'Haens
, Ron Mathôt

University of Ljubljana
Department of Gastroenterology and Hepatology
KU Leuven
Uppsala University
Radboud University Nijmegen
Imelda Hospital
AZ Delta
UMC Amsterdam Amsterdam, the Netherlands

Research output: Contribution to journal › Comment/Letter to the editor › Academic

15 Downloads (Pure)

Abstract

In the originally published version of this manuscript, reference 36 incorrectly read "Sandborn WJ, Ghosh S, Panes J, et al. Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis. Gastroenterology. 2020;158:2139-2149.e14". It should have read "Sandborn WJ, Baert F, Danese S, et al. Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis. Gastroenterology. 2020;158(3):562-572 e512." This has now been corrected online.

Original language	English
Pages (from-to)	817
Number of pages	1
Journal	Inflammatory bowel diseases
Volume	28
Issue number	5
DOIs	https://doi.org/10.1093/ibd/izab270
Publication status	Published - 1 May 2022

Access to Document

10.1093/ibd/izab270

izab270.pdfFinal published version, 84.8 KB

Fingerprint

Dive into the research topics of 'Erratum: Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients with Crohn Disease: Posthoc Analysis of the LOVE-CD Study (Inflammatory Bowel Diseases DOI: 10.1093/ibd/izab143)'. Together they form a unique fingerprint.

Cite this

Hanzel, J., Dreesen, E., Vermeire, S., Löwenberg, M., Hoentjen, F., Bossuyt, P., Clasquin, E., Baert, F. J., D'Haens, G. R., & Mathôt, R. (2022). Erratum: Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients with Crohn Disease: Posthoc Analysis of the LOVE-CD Study (Inflammatory Bowel Diseases DOI: 10.1093/ibd/izab143). Inflammatory bowel diseases, 28(5), 817. https://doi.org/10.1093/ibd/izab270

@article{0652a4b27b1344bcac1933c798c7daf9,

title = "Erratum: Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients with Crohn Disease: Posthoc Analysis of the LOVE-CD Study (Inflammatory Bowel Diseases DOI: 10.1093/ibd/izab143)",

abstract = "In the originally published version of this manuscript, reference 36 incorrectly read {"}Sandborn WJ, Ghosh S, Panes J, et al. Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis. Gastroenterology. 2020;158:2139-2149.e14{"}. It should have read {"}Sandborn WJ, Baert F, Danese S, et al. Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis. Gastroenterology. 2020;158(3):562-572 e512.{"} This has now been corrected online.",

author = "Jurij Hanzel and Erwin Dreesen and S{\'e}verine Vermeire and Mark L{\"o}wenberg and Frank Hoentjen and Peter Bossuyt and Esm{\'e} Clasquin and Baert, \{Filip J.\} and D'Haens, \{Geert R.\} and Ron Math{\^o}t",

year = "2022",

month = may,

day = "1",

doi = "10.1093/ibd/izab270",

language = "English",

volume = "28",

pages = "817",

journal = "Inflammatory bowel diseases",

issn = "1078-0998",

publisher = "John Wiley and Sons Inc.",

number = "5",

}

Hanzel, J, Dreesen, E, Vermeire, S, Löwenberg, M, Hoentjen, F, Bossuyt, P, Clasquin, E, Baert, FJ, D'Haens, GR & Mathôt, R 2022, 'Erratum: Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients with Crohn Disease: Posthoc Analysis of the LOVE-CD Study (Inflammatory Bowel Diseases DOI: 10.1093/ibd/izab143)', Inflammatory bowel diseases, vol. 28, no. 5, pp. 817. https://doi.org/10.1093/ibd/izab270

Erratum: Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients with Crohn Disease: Posthoc Analysis of the LOVE-CD Study (Inflammatory Bowel Diseases DOI: 10.1093/ibd/izab143). / Hanzel, Jurij; Dreesen, Erwin; Vermeire, Séverine et al.
In: Inflammatory bowel diseases, Vol. 28, No. 5, 01.05.2022, p. 817.

Research output: Contribution to journal › Comment/Letter to the editor › Academic

TY - JOUR

T1 - Erratum

T2 - Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients with Crohn Disease: Posthoc Analysis of the LOVE-CD Study (Inflammatory Bowel Diseases DOI: 10.1093/ibd/izab143)

AU - Hanzel, Jurij

AU - Dreesen, Erwin

AU - Vermeire, Séverine

AU - Löwenberg, Mark

AU - Hoentjen, Frank

AU - Bossuyt, Peter

AU - Clasquin, Esmé

AU - Baert, Filip J.

AU - D'Haens, Geert R.

AU - Mathôt, Ron

PY - 2022/5/1

Y1 - 2022/5/1

N2 - In the originally published version of this manuscript, reference 36 incorrectly read "Sandborn WJ, Ghosh S, Panes J, et al. Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis. Gastroenterology. 2020;158:2139-2149.e14". It should have read "Sandborn WJ, Baert F, Danese S, et al. Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis. Gastroenterology. 2020;158(3):562-572 e512." This has now been corrected online.

AB - In the originally published version of this manuscript, reference 36 incorrectly read "Sandborn WJ, Ghosh S, Panes J, et al. Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis. Gastroenterology. 2020;158:2139-2149.e14". It should have read "Sandborn WJ, Baert F, Danese S, et al. Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis. Gastroenterology. 2020;158(3):562-572 e512." This has now been corrected online.

UR - https://www.scopus.com/pages/publications/85129997504

U2 - 10.1093/ibd/izab270

DO - 10.1093/ibd/izab270

M3 - Comment/Letter to the editor

C2 - 34788812

SN - 1078-0998

VL - 28

SP - 817

JO - Inflammatory bowel diseases

JF - Inflammatory bowel diseases

IS - 5

ER -

Hanzel J, Dreesen E, Vermeire S, Löwenberg M, Hoentjen F, Bossuyt P et al. Erratum: Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients with Crohn Disease: Posthoc Analysis of the LOVE-CD Study (Inflammatory Bowel Diseases DOI: 10.1093/ibd/izab143). Inflammatory bowel diseases. 2022 May 1;28(5):817. doi: 10.1093/ibd/izab270

Erratum: Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients with Crohn Disease: Posthoc Analysis of the LOVE-CD Study (Inflammatory Bowel Diseases DOI: 10.1093/ibd/izab143)

Abstract

Access to Document

Other files and links

Fingerprint

Cite this